Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-dense FEC followed by Docetaxel vs Paclitaxel in Node-Positive Breast Cancer
NCT00431080Phase 3Completed
- Sponsor
- Hellenic Oncology Research Group
- Start
- Aug 2004
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel in breast cancer (2 arms), sponsored by Hellenic Oncology Research Group. Primary endpoint: Disease-Free Survival at 3 years. Started Aug 2004; status: completed.
02
Drugs
docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00431080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00431080.